Clinical trial · Interventional
Rollover Protocol for Prior SU011248 Protocols
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol
NCT00798889CI-TRIAL-00009022completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sunitinib
- interventionNames
- Drug: Sunitinib
Primary outcomes (1)
- measure
- Duration of Treatment
- timeFrame
- Baseline up to Day 28 after last dose of study treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Prior SU011248 Protocol. * Eligible to continue SU011248 treatment. Exclusion Criteria: * Uncontrolled CNS metastasis. * Unfit to receive SU011248.
References
Publications (0)
Data not yet available
No reference posted for this study.